Koninklijke Philips Nv Stock Earnings Reports

Philips delivered a strong start to 2026 with continued order momentum, modest sales growth and margin expansion. Q1 order intake grew 6% and comparable sales increased ~4% (group comparable sales +3.7%); adjusted EBITDA margin improved 40 bps to 9.0% (adjusted EBITDA margin guidance for full year reiterated at 12.5%–13%). Segment highlights: Diagnosis & Treatment (D&T) saw mid-single-digit order intake driven by Image Guided Therapy (Azurion) and MRI (BlueSeal helium-free systems); Connected Care grew driven by monitoring and enterprise informatics (enterprise monitoring-as-a-service traction); Personal Health delivered strong broad-based growth (+9% comparable), led by product launches (e.g., Shaver 9000/i9000, Sonicare range) and expanded distribution. Innovation momentum: regulatory clearances accelerated (20 510(k)/PMAs in Q1), launches include Verida spectral CT and AI-enabled solutions (SmartHeart, DeviceGuide, IntraSight Plus). Execution: productivity delivery of EUR 126m in Q1 toward a EUR 1.5bn three-year target; field actions reduced and supply chain regionalized. China remains subdued due to expanding centralized procurement (pressure on CT and ultrasound), but Philips is focused on higher-differentiated modalities (MR, IGT). Financials and cash: net income improved to EUR 146m, adjusted EPS EUR 0.23, free cash flow EUR +28m (improved vs. prior year ex-settlement), net debt EUR 5.5bn and leverage ~1.8x. Management reiterated full-year comparable sales growth guidance (3%–4.5%) and free cash flow guidance of EUR 1.3bn–1.5bn, while calling out ongoing macro/tariff/input-cost uncertainty and mitigation actions (productivity, selective pricing, supply chain optimization). Key risks include cost inflation (freight, components, plastics), geopolitical developments (Middle East) and ongoing regulatory/legal matters excluded from guidance (Respironics/DOJ).